Trial Profile
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary) ; Capecitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms JANUS 2
- Sponsors Incyte Corporation
- 29 Jul 2021 This trial has been completed in Denmark (End Date: 14 Oct 2016), according to European Clinical Trials Database record.
- 06 Mar 2018 Primary endpoint (Overall Survival (OS)) has not been met as per the results published in the Investigational New Drugs
- 06 Mar 2018 Results assessing safety and efficacy published in the Investigational New Drugs